CoSyne Therapeutics Raises £3.3M to Use Computational Systems Biology to Beat Glioblastoma
August 8, 2024
CoSyne Therapeutics, a UK-based biotechnology company, has raised £3.3 million to advance its computational systems analysis platform for drug development in glioblastoma multiforme (GBM), the most aggressive and lethal form of primary brain cancer. The company applies systems biology — the study of how components of a biological system interact as a whole, rather than in isolation — to understand the complex network of signalling pathways that drive GBM's resistance to treatment and to identify combination drug strategies with genuine potential to break through that resistance.
GBM carries one of the most dispiriting prognoses in oncology. The current standard of care — surgery followed by radiotherapy and temozolomide chemotherapy — has remained largely unchanged for two decades. Median survival after diagnosis is approximately 15 months, and the five-year survival rate is below five percent. Dozens of targeted therapies that have shown early promise in GBM have failed in clinical trials, in part because the tumour's extreme genetic heterogeneity and its ability to rapidly rewire signalling networks in response to therapeutic pressure make single-agent targeting strategies almost always insufficient. The tumour consistently finds routes around any single blockade.
CoSyne's approach addresses this by modelling the tumour's signalling network computationally — using systems analysis techniques drawn from engineering and mathematics to simulate how different pathway combinations interact, and to predict which combination perturbations are most likely to overwhelm the tumour's adaptive capacity. This enables the company to generate and prioritise combination therapy hypotheses that would be impractical to screen experimentally at scale, and to design experiments that test the most promising predictions with maximum information content. The platform integrates molecular data, patient data, and pharmacological data to build tumour models that are specific to GBM's unique biology rather than generic cancer pathway models.
The funding will support the expansion of CoSyne's computational platform, the validation of its lead combination hypotheses in preclinical models, and the development of the evidence base needed to advance towards clinical investigation. The raise reflects growing investor recognition that computational approaches to oncology drug discovery — particularly in resistant tumours like GBM — can substantially improve the probability of clinical success by more rigorously characterising the disease before committing to a clinical programme.
Sources
Thank you to our Patrons & Partners:
